Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever

Trabulus S. , Korkmaz M., Kaya E., Seyahi N.

CLINICAL TRANSPLANTATION, cilt.32, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 32 Konu: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/ctr.13345


Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.